Efficacy and safety of plasmapheresis in symptomatic hyperviscosity and cast nephropathy: A Multicenter Experience in Turkey

Basit Öğe Kaydı
dc.contributor.authorKalpakci, Yasin
dc.contributor.authorHacibekiroglu, Tuba
dc.contributor.authorDarcin, Tahir
dc.contributor.authorAkgunCagliyan, Gulsum
dc.contributor.authorCakar, Merih Kizil
dc.contributor.authorHacioglu, Sibel Kabukcu
dc.contributor.authorEkinci, Omer
dc.date.accessioned2024-04-24T16:18:31Z
dc.date.available2024-04-24T16:18:31Z
dc.date.issued2021
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground and objectives: Cast nephropathy (CN) and hyperviscosity (HV), which we encounter in plasma cell diseases, are serious clinical manifestations that increase mortality and morbidity if not managed well in the early period. Therapeutic plasma exchange (TPE) procedures based on the removal of patient plasma is a frequently preferred treatment modality. TPE is recommended at varying levels of evidence for the treatment of CN and HV in plasma cell disorders. Material and methods: A total of 61 patients, 50 with multipl myeloma (MM) and 10 with Waldenstro spacing diaeresis m macroglobulinemia (WM), who underwent TPE for CN and HV, were included in our multicenter, and retrospective study. Results: A statistically significant decrease was found in all disease-related biochemical markers, which were measured 1 week after the application of TPE added to standard medical treatment (IgG; p < 0.001, IgM; p = 0.004, IgA; p = 0.14, kappa light chain; p < 0.001, lambda light chain; p < 0.001, beta-2 microglobulin; p < 0.001, total protein; p < 0.001, albumin; p < 0.001, LDH; p = 0.02, creatine; p < 0.001, hemoglobin; p = 0.010). Clinically, all 11 patients who underwent TPE for HV responded. While a partial response (PR: 80 %) was obtained in 40 of 50 MM patients with CN, no response was obtained in 10 patients (non-response: 20 %). Conclusion: In conclusion, it was observed that TPE reduced all biochemical markers related to HV and CN, while making a significant contribution to clinical improvement. We believe that adding TPE to the standard treatment in this patient group will reduce mortality and morbidity in the early period and have a positive effect on survival in the long term.en_US
dc.identifier.doi10.1016/j.transci.2021.103244
dc.identifier.issn1473-0502
dc.identifier.issn1878-1683
dc.identifier.issue5en_US
dc.identifier.pmid34462219
dc.identifier.urihttps://doi.org/10.1016/j.transci.2021.103244
dc.identifier.urihttps://hdl.handle.net/11468/16146
dc.identifier.volume60en_US
dc.identifier.wosWOS:000697004600025
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofTransfusion and Apheresis Science
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPlasmapheresisen_US
dc.subjectSymptomatic Hyperviscosityen_US
dc.subjectCast Nephropathyen_US
dc.subjectEfficacyen_US
dc.subjectSafetyen_US
dc.titleEfficacy and safety of plasmapheresis in symptomatic hyperviscosity and cast nephropathy: A Multicenter Experience in Turkeyen_US
dc.titleEfficacy and safety of plasmapheresis in symptomatic hyperviscosity and cast nephropathy: A Multicenter Experience in Turkey
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu